Titan Bio-Tech (TITANBIO) | Stock Overview & Key Data
Titan Bio-Tech Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,460.00 on February 18, 2026
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Titan Bio-Tech
TITANBIO
|
19.90B Small-cap | 3.09% | -1.02% | 28.03% | 96.24% | 110.92% | 419.45% | 756.94% | 499.88% | 6,742.31% | 9,962.22% | 20,395.39% |
|
Biocon
BIOCON
|
566.52B Large-cap | 1.66% | -3.27% | 10.34% | 6.50% | 7.30% | 17.90% | 71.09% | 5.03% | 250.57% | 603.49% | 1,357.39% |
|
OneSource Specialty
ONESOURCE
|
202.76B Large-cap | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
|
Zota Health Care
ZOTA
|
39.41B Small-cap | 3.68% | 3.22% | 14.06% | -26.10% | -17.99% | 27.17% | 243.00% | 632.12% | 1,248.00% | 1,248.00% | 1,248.00% |
|
Dishman Carbogen
DCAL
|
26.50B Small-cap | -2.24% | -7.21% | 9.02% | -19.76% | -29.73% | -33.95% | 46.77% | -6.77% | 33.46% | 290.77% | 118.12% |
|
Panacea Biotec
PANACEABIO
|
21.84B Small-cap | -2.19% | 39.94% | 70.71% | 51.42% | 43.20% | 18.85% | 307.76% | 44.67% | 440.21% | 276.43% | 141.23% |
Ownership & Short Interest
Calculate Your Titan Bio-Tech Investment Returns
Long-Term Investment Performance Analysis
Titan Bio-Tech stock price in Jul 2016 was ₹6.99, A ₹1,000.00 lump sum investment in Titan Bio-Tech made 9 years ago would be worth approximately ₹64,134.48 today, representing a exceptional return of 6,313.45%. This translates to an annualized return (CAGR) of 52.19%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is TITANBIO's 52-week high and low?
- In the last 52 weeks, Titan Bio-Tech reached a high of ₹555.65 (on April 7, 2026) and a low of ₹74.73 (on N/A).
- What is the market cap and P/E ratio for TITANBIO?
- Curious about Titan Bio-Tech's size and valuation? Its market capitalization stands at 19.90B. When it comes to valuation, the P/E ratio (trailing twelve months) is 74.64, and the forward P/E (looking ahead) is N/A.
- Does TITANBIO pay dividends? If so, what's the yield?
- Yes, Titan Bio-Tech is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.42%, and the company has paid an average of ₹1.93 per share annually over the past 3 years.
- Who are Titan Bio-Tech's main competitors or similar companies to consider before investing?
When looking at Titan Bio-Tech, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON566.52B Healthcare Biotechnology 17.90% 71.09% OneSource Specialty
ONESOURCE202.76B Healthcare Biotechnology -20.38% -5.70% Zota Health Care
ZOTA39.41B Healthcare Biotechnology 27.17% 243.00% Dishman Carbogen
DCAL26.50B Healthcare Biotechnology -33.95% 46.77% Panacea Biotec
PANACEABIO21.84B Healthcare Biotechnology 18.85% 307.76% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Titan Bio-Tech Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Titan Bio-Tech's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.04%, the Debt to Equity ratio from the most recent quarter is 5.32, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for TITANBIO?
- Looking at Titan Bio-Tech's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 47.60%, and quarterly earnings saw a YoY growth of 94.30%.
- How much of TITANBIO stock is held by insiders and institutions?
- Wondering who owns Titan Bio-Tech stock? Company insiders (like executives and directors) hold about 68.21% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.